
Research presented Thursday at the annual meeting of the American Society of Tropical Medicine and Hygiene has revealed complications with combining a monoclonal antibody and malaria vaccine in infants. Scientists conducted a trial in Mali using L9LS, an injection designed to provide months of protection against malaria parasites. The antibody demonstrated 78% effectiveness against the parasite over a six-month transmission season, comparable to previous studies in older children and adults.
However, the investigation uncovered a significant interaction problem. When infants received L9LS followed by doses of the R21 malaria vaccine, the monoclonal antibody interfered with the immune response generated by the vaccination. This interference resulted in a 20% to 30% reduction in antibody levels produced by the immunization. Researchers believe this occurred because both L9LS and R21 target the same protein on the parasite, known as the circumsporozoite protein, causing the monoclonal to bind to the vaccine and suppress its intended immune training effect.
Given these findings, researchers have adjusted their approach. They plan to focus on alternative populations for pivotal studies that could lead to L9LS approval, with trials tentatively scheduled to begin in 2028. Potential candidates include pregnant individuals, who face heightened risks from malaria infection, and hospitalized children recovering from the disease who remain vulnerable to severe outcomes during their recovery period.
Experts emphasized that malaria prevention requires multiple strategies given limited funding and the disease’s predominant impact on low-income countries. The infection caused approximately 610,000 deaths in 2024, primarily affecting children under 5 in sub-Saharan Africa. While the R21 and RTS,S vaccines represent scientific breakthroughs as the first parasitic vaccines, they require multiple doses and years to reach full effectiveness. A single-dose monoclonal offers logistical advantages, though cost remains a constraint compared to existing preventive medications, which are inexpensive but face adherence challenges.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI